One of the Company's strategic priorities is to broaden its product range, leveraging its innovative and experienced R&D capability whilst being mindful of costs and focusing on return on investment for shareholders.
Eroxon® Intense provides a potential range extension of the current Eroxon® product and acts as an additional treatment option for men who have erectile dysfunction, helping those men that may prefer a stronger sensation from Eroxon®.
Marketing experience with Eroxon® has shown that whilst many men are satisfied with the current sensorial effect of the product, some men would prefer a stronger sensation. Eroxon® Intense will help those men, thereby broadening the existing Eroxon® range.
Enhanced formulation in proof of concept study
In a single-blind randomised crossover design study, 16 male subjects blind tested three enhanced formulations compared with Eroxon®. 67% of the men experienced greater sensorial sensitivity on the preferred formulation compared to Eroxon®. A preferred enhanced formulation with a favourable side effect profile has now been selected for further consumer testing during H1 2025, with regulatory approval in the EU and USA expected by the end of 2025.
Commercial outlook
The Company's commercial partners have shown strong interest for new variants beyond the original Eroxon® product to expand the product range as they seek to build out the sexual health category within their own businesses and meet retailers expectations for product line extensions. Therefore, an additional treatment option for erectile dysfunction that is aimed at helping the cohort of men that may prefer a stronger sensation from Eroxon® is commercially attractive to support users' needs as well as commercial partners' strategic ambitions. Eroxon® Intense will be covered under Futura's existing intellectual property.